Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data

Protagonist Therapeutics, Inc

Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.
Phase 3 ICONIC-LEAD: 65% IGA 0/1 and 50% PASI 90 at Wk16; at Wk24: 74% IGA 0/1, 65% PASI 90; 46% completely clear skin.
Phase 3 ICONIC-ADVANCE 1&2: met co-primary endpoints vs placebo; superior to deucravacitinib on all key secondary endpoints at Wk16 and Wk24.
Initiation of ICONIC-ASCEND: first head-to-head study of oral icotrokinra vs injectable biologic (ustekinumab) in moderate-to-severe PsO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.